Shares of bluebird bio fell in trading after the company announced that the sickle cell disease gene therapy treatment bb1111 will not be submitted to the U.S. Food and Drug Administration for two more years.

Cerevel Therapeutics began trading on the Nasdaq.

Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.

Shares of Cara Therapeutics were up in trading after the company struck a licensing agreement worth up to $290 million with Switzerland’s Vifor Pharma for the commercialization of a treatment for severe itching associated with chronic kidney disease.

Shares of Voyager Therapeutics were down in trading after the company announced a clinical hold was placed on an experimental gene therapy treatment for Huntington’s disease before heading into the clinic.

Shares of Avenue Therapeutics plunged in trading after the company announced the U.S. Food and Drug Administration rejected the New Drug Application for intravenous tramadol over safety concerns.

Shares of Solid Biosciences skyrocketed in trading after the company announced the U.S. Food and Drug Administration lifted the clinical hold on the IGNITE DMD Phase I/II clinical trial.

Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.

Germany’s CureVac NV started a mid-stage study testing the company’s experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter of 2020.

Endo said the company was manufacturing Novavax’s experimental Covid-19 vaccine, sending the generic drugmaker’s shares up 10% in trading.